GlassScriptPhysician profile
Kayley Erickson
NPI 1881396745
$1,183.39
in general payments reported to CMS, 2019-2025
12 companies · $993 in 2025
The $993 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $191 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $287.47 | 2025 | Vtama |
| Ucb, INC. | $287.41 | 2024-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $191.25 | 2025 | |
| Janssen Scientific Affairs, LLC | $119.47 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $107.18 | 2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.03 | 2025 | Spevigo |
| Sun Pharmaceutical Industries INC. | $37.24 | 2025 | |
| Amgen INC. | $32.56 | 2024-2025 | Otezla |
| Helsinn Therapeutics (U.S.), INC. | $22.99 | 2025 | Valchlor |
| Lilly USA, LLC | $20.61 | 2025 | Ebglyss |
| Regeneron Healthcare Solutions, INC. | $16.88 | 2025 | Dupixent |
| Janssen Biotech, INC. | $14.30 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayley Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.